{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-24-000096","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.355804+00:00","generated_at":"2026-05-31T14:11:43.991887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Labcorp Q2 revenue $3.22B (+6.2%), adj EPS $3.94; raises revenue guidance, boosts buyback $1B","bullets":["Q2 revenue $3.22B (+6.2% YoY); diluted EPS $2.43 vs $1.74; adjusted EPS $3.94 vs $3.42.","Free cash flow $432.9M vs $58.2M a year ago.","Updated FY 2024 guidance: revenue growth 6.4%-7.5% (prior 4.8%-6.4%); adj EPS $14.30-$14.90 (incl. ~$0.40 Invitae dilution).","Board approved $1.0B increase in share repurchase authorization to $1.4B; quarterly dividend $0.72/share.","Invitae acquisition expected close early August; launched FDA-approved hemophilia B CDx and preeclampsia screening."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-24-000096","json":"https://secwatch.observer/filing/0000920148-24-000096.json","markdown":"https://secwatch.observer/filing/0000920148-24-000096.md","text":"https://secwatch.observer/filing/0000920148-24-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014824000096/0000920148-24-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014824000096/lh-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:11:43.991887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}